Previous Close | 1.6200 |
Open | 1.6500 |
Bid | 0.7500 |
Ask | 1.9500 |
Strike | 12.50 |
Expire Date | 2024-07-19 |
Day's Range | 1.6200 - 1.6500 |
Contract Range | N/A |
Volume | |
Open Interest | 24 |
REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as REGENXBIO
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
Key Insights REGENXBIO will host its Annual General Meeting on 31st of May Total pay for CEO Ken Mills includes...